DCA Inc. dba Beacon Prescriptions

CLOSEOUT LETTER DCA Inc. dba Beacon Prescriptions MARCS-CMS 525833 — September 22, 2021 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Reference #: 3005823862 Product: Drugs Recipient: Recipient Name Annik S. Chamberlin Recipient Title PharmD DCA Inc. dba Beacon Prescriptions 690 North Main Street Southington , CT 06489-2529 United States Issuing Office: OPQO Division I / New Jersey District United States (973) 331-4900 Dear Dr. Chamberlin: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [WL #525833], dated June 1, 2017. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. If you have any questions, contact Compliance Officer Juan Jimenez at orapharm1_responses@fda.hhs.gov ; and juan.jimenez@fda.hhs.gov . Please identify correspondence with FEI # 3005823862. Sincerely, Diana Amador-Toro Program Division Director/District Director U.S. Food and Drug Administration OPQO Division I / New Jersey District Diana Amadortoro -S Digitally signed by Diana Amador-toro -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1 Content current as of: 09/28/2021 Regulated Product(s) Drugs